ArticleTranslational andrology and urology2026

First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma-commentary on patient-reported outcomes in EV-302.

Fredrik Liedberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.